Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 72% CR at any point in time.

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Apr 30, 2023 7:55pm

254 Views

Post# 35422057

RE:RE:RE:RE:RE:RE:72% CR at any point in time.

Yes, we need clarification. It seems a very odd procedure to update the 90 day column and not do so for the other time periods in the very same table without even commenting about it. Was the deceased patient ever included in the data? He/she died before their 90 day assessment. I suppose 2 patients could have dropped out.

enriquesuave wrote:
Eoganacht wrote: I hope they have eliminated the first 12 undertreated patents. But I don't think that alone can account for the 12 evaluable patients at 450 days. In the Nov. 29 MD&A there were 29 evaluable patients at 450 days. If we remove the 12 undertreated and the 3 from phase 1 we would have 14 patients. It has been 5 months since Nov 29 and 5 patients who were evaluated at 360 days should now also have been evaluated at 450 days. That would make 19 patients evaluated at 450 days. There are now only 12.

enriquesuave wrote:
wildbird1 wrote: NotinKansas, you start your post exactly the same way that greaterfoolfred does, by saying something that is misleading.

You pretend that the NR patients collect at the bottom. How do you explain patient 22 , this patient is NR from 90 days up to 360 days, and he is not at the bottom of the Swimmer plot.
And there is absolutely no mention anywhere in any Pressrelease that say that the NR patients are send at the bottom of the Swimmer list.

It's obvious from chart and swimmers plot mirrors chart. 52 patients plus 4 non evaluable patients for a total of 56. Includes 12 undetreated at 90 days. Other time points the 12 under treated were removed. Now if in another trial patients were to be given 100 mg of a drug, but 12 patients were wrongly given 15-59 mg ( or 15-59% of intended dose), why in the hell should they be included in final data? Only to be used in safety analysis perhaps? That's what happened with the 12 under treated. It was just a matter of time before removal from data. IMHO

Hope we see more details from AUA presentation. I see one missing patient plus no new data yet presented other than at 90 days in MD&A. 29 -12 - 3 - 1 = 13. 12 undertreated, 3 from PH1 and 1 who died. Maybe one more who dropped out?